Every year the European Association of Urology (EAU) hosts Urology Week, an international campaign for increasing awareness of urological conditions and treatment. This year, Urology Week (26-30 September… read more.
Current guidelines recommend a repeat TUR (re-TUR) for T1 bladder tumours but this carries risks and could be avoided if a good, complete TUR is done in the… read more.
According to the updated EAU guidelines long-term survival with trimodality bladder preserving treatment (TMT) could be as good as with radical cystectomy (RC), in selected patients. During the… read more.
Trimodality bladder preserving treatment (TMT) for muscle invasive bladder cancer is gaining ground but careful patient selection is essential for success – only 10-20 percent of cases fit… read more.
For many years surgery has been regarded as the gold standard for MIBC but now comparative trials, epidemiological findings and a meta-analysis of trials all show that outcomes… read more.
Intravesical therapy with chemotherapy or BCG is the recommended adjuvant treatment after TURBT to minimise the risk of recurrence. BCG shortages continue and BCG is not suitable for… read more.
The introduction of immunotherapy with immune checkpoint inhibitors has improved outcomes in trials. In this video Professor Morgan Roupret explains the current situation regarding immunotherapy and bladder cancer: This session… read more.